TABLE 1.
Percent susceptible to ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators among all P. aeruginosa isolates and subsets of MDR, pan-β-lactam-nonsusceptible, and DTR isolatesa
| Phenotype | No. (% of all isolates) | Antimicrobial agent, % susceptible |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/T | IMR | CZA | TZP | FEP | CAZ | MEM | IMI | ATM | AMK | LVX | ||
| All | 2,531 (100) | 96.4 | 91.5 | 94.4 | 77.0 | 81.6 | 79.9 | 78.3 | 66.0 | 69.9 | 97.0 | 66.8 |
| MDR | 319 (12.6) | 75.9 | 58.9 | 63.3 | 8.8 | 12.2 | 16.6 | 19.7 | 16.3 | 3.8 | 84.0 | 18.5 |
| Pan-β-lactam-NS | 207 (8.2) | 73.4 | 51.2 | 50.2 | 0 | 0 | 0 | 0 | 0 | 0 | 84.5 | 15.9 |
| DTR | 169 (6.7) | 69.8 | 46.2 | 45.0 | 0 | 0 | 0 | 0 | 0 | 0 | 82.8 | 0 |
C/T, ceftolozane-tazobactam; IMR, imipenem-relebactam; CZA, ceftazidime-avibactam; TZP, piperacillin-tazobactam; FEP, cefepime; CAZ, ceftazidime; MEM, meropenem; IMI, imipenem; ATM, aztreonam; AMK, amikacin; LVX, levofloxacin; NS, nonsusceptible; R, resistant; MDR, multidrug-resistant (resistant to ≥3 sentinel agents [AMK, ATM, FEP, colistin, IMI, LVX, and TZP]); pan-β-lactam-NS, nonsusceptible to all tested β-lactams (excluding C/T, IMR, and CZA); DTR, difficult-to-treat resistance (nonsusceptible to all tested β-lactams, excluding C/T, IMR, and CZA, and fluoroquinolones).